Measurement of Midazolam Levels in Follicular Fluid

Measurement of Midazolam Levels in Follicular Fluid and Correlation of Midazolam Levels in Follicular Fluid and Oocyte Quality, Fertilization Rate, Embryo Development Pattern and Euploid Status

Status

Terminated

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03049293

Enrollment

Registered

2017-02-10

Start date

2017-06-20

Completion date

2019-10-01

Last updated

2021-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Midazolam Overdose

Keywords

COPD,IVF

Brief summary

To determine the impact of Midazolam levels in follicular fluid on morpho-kinetics and morpho-genetics. The reason to measure Midazolam levels in larger size follicles in this study is to maximize the chances to get a mature oocyte and therefore develop into a potential embryo to be analyzed.

Detailed description

The correlation of Midazolam levels in follicular fluid and euploid status of the embryos is worth exploring as no data exists that suggests any influence on the quality of the embryos from using this substance for IVF since its earliest days. Measuring time lapsed from injection to first oocyte retrieval as well as time lapsed in between first and last oocyte retrieved will grand insight into the rise of levels of Midazolam inside the follicular fluid, correlated with the chromosomal status and the morphokinetic development of the euploid embryos.

Interventions

DRUGMidazolam

The impact of Midazolam levels in follicular fluid.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Yes

Inclusion criteria

* Infertility (prim. / sec.) * Age \>18 - ≤ 38 years. * BMI 19-30 * Stimulation in GnRH-antagonist protocol, using rFSH * Expected normal ovarian response (6) * At least 4 follicles with the size ≥ than 17 mm on the day of OPU * Patients undergoing PGS * Able to understand the aim of the study and to provide consent

Exclusion criteria

* History of endometriosis, classified according to the American Fertility Society (AFS) as stage 3 or more. * Severe male factor

Design outcomes

Primary

Measure	Time frame	Description
Midazolam values measured by the time from the injection of Midazolam to the oocyte aspiration .	6-12 months	To determine the impact of Midazolam levels in follicular fluid on morpho-kinetics and morpho-genetics.

Countries

United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026